These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 22263704

  • 1. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
    Frankel HC, Qureshi AA.
    Am J Clin Dermatol; 2012 Apr 01; 13(2):113-23. PubMed ID: 22263704
    [Abstract] [Full Text] [Related]

  • 2. Topical tacrolimus for atopic dermatitis.
    Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM.
    Cochrane Database Syst Rev; 2015 Jul 01; 2015(7):CD009864. PubMed ID: 26132597
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
    Breuer K, Werfel T, Kapp A.
    Am J Clin Dermatol; 2005 Jul 01; 6(2):65-77. PubMed ID: 15799678
    [Abstract] [Full Text] [Related]

  • 5. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
    Garside R, Stein K, Castelnuovo E, Pitt M, Ashcroft D, Dimmock P, Payne L.
    Health Technol Assess; 2005 Jul 01; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
    [Abstract] [Full Text] [Related]

  • 6. The role of topical calcineurin inhibitors in atopic dermatitis.
    Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K, European Working Group on Atopic Dermatitis.
    Br J Dermatol; 2004 Dec 01; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
    [Abstract] [Full Text] [Related]

  • 7. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis.
    Chia BK, Tey HL.
    Dermatitis; 2015 Dec 01; 26(3):122-32. PubMed ID: 25984688
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS.
    J Dermatol Sci; 2009 May 01; 54(2):76-87. PubMed ID: 19303745
    [Abstract] [Full Text] [Related]

  • 11. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
    Thaçi D, Salgo R.
    Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun 01; 16(2):58, 60-62. PubMed ID: 17992459
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec 01; 13(74):209-12. PubMed ID: 15599989
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
    Schneeweiss S, Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, Seeger JD.
    Dermatology; 2009 Dec 01; 219(1):7-21. PubMed ID: 19293564
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.